(Q42272307)

19 October 2017

title

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study (English)

1 reference

19 October 2017

1 reference

1 reference

14

1 reference

19 October 2017

15

1 reference

19 October 2017

Ming Yao

5

0 references

Tien Hwei-fang

object named as

Hwei-Fang Tien

12

0 references

Woei-Yau Kao

7

object named as

Woei-Yau Kao

1 reference

19 October 2017

8

Chang-Fang Chiu

1 reference

19 October 2017

11

Cheng-Shyong Chang

1 reference

19 October 2017

Chiun Hsu

1

1 reference

19 October 2017

Hsiao-Hui Tsou

2

1 reference

19 October 2017

Shyh-Jer Lin

3

1 reference

19 October 2017

Ming-Chung Wang

4

1 reference

19 October 2017

Wen-Li Hwang

6

1 reference

19 October 2017

Sheng-Fung Lin

9

1 reference

19 October 2017

Johnson Lin

10

1 reference

19 October 2017

Tsang-Wu Liu

13

1 reference

19 October 2017

Taiwan Cooperative Oncology Group

16

1 reference

19 October 2017

language of work or name

English

0 references

publication date

14 April 2014

1 reference

19 October 2017

1 reference

19 October 2017

volume

59

1 reference

19 October 2017

issue

6

1 reference

19 October 2017

page(s)

2092-2100

1 reference

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

19 October 2017

cites work

1 reference

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma

21 January 2018

1 reference

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study

21 January 2018

1 reference

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

21 January 2018

1 reference

Does rituximab increase the incidence of infectious complications? A narrative review

21 January 2018

1 reference

Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.

21 January 2018

1 reference

Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers

21 January 2018

1 reference

Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy

21 January 2018

1 reference

Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis

21 January 2018

1 reference

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

New insight in the pathobiology of hepatitis B virus infection

21 January 2018

1 reference

Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients.

21 January 2018

1 reference

Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean

21 January 2018

1 reference

Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?

21 January 2018

1 reference

Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.26718

1 reference

19 October 2017

1 reference